Cellectis S.A. in brief
Cellectis S.A. is a listed company in the Biotechnology industry, based in Paris, France. Its last known market value was $216 M (January 2024); there is no current figure. In the year to December 2025 it had sales of $73 M and a net loss of $68 M. By market, the largest shares of its 2025 sales came from France (100%). Its shares trade under the symbol ALCLS.PA (EURONEXT).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
Cellectis S.A. timeline
- 2015
- 🔔· approximateInitial public offering on EURONEXT
Events of Cellectis S.A. from the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in France: #173 (Jan 2020) · #132 (Jan 2021) · #230 (Jan 2022) · #330 (Dec 2022) · #305 (Jul 2023) · #235 (Jan 2024)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin (TTM)
- -92.7%
- Operating margin
- -45.3%
- Return on equity
- -89.1%
- Liabilities / assets
- 76.6%
- Revenue growth
- +75.8%
- R&D / revenue
- 128.2%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $73M | +75.8% | $-33M | $-68M | -92.7% |
| Dec 2024 | $42M | +5360.5% | $-60M | $-37M | -88.6% |
| Dec 2023 | $1M | -96.0% | $-97M | $-101M | -13297.4% |
| Dec 2022 | $19M | -36.8% | $-90M | $-106M | -553.7% |
| Dec 2021 | $30M | -40.6% | $-103M | $-114M | -376.3% |
| Dec 2020 | $51M | +236.1% | $-42M | $-81M | -158.8% |
| Dec 2019 | $15M | +19.3% | $-124M | $-102M | -672.1% |
| Dec 2018 | $13M | — | $-105M | $-79M | -618.1% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-39M | $2M | $-42M | $-0.67 | — |
| Dec 2024 | $23M | $3M | $20M | $-0.41 | — |
| Dec 2023 | $-25M | $1M | $-26M | $-1.77 | — |
| Dec 2022 | $-87M | $2M | $-90M | $-2.33 | — |
| Dec 2021 | $-105M | $19M | $-123M | $-2.55 | — |
| Dec 2020 | $-80M | $44M | $-124M | $-1.91 | — |
| Dec 2019 | $-69M | $13M | $-82M | $-2.41 | — |
| Dec 2018 | $-68M | $5M | $-73M | $-1.93 | — |
SEC filings
- Nov 12, 20266-KReport of foreign issuer
- Nov 9, 20266-KReport of foreign issuer
- Oct 28, 20266-KReport of foreign issuer
- Sep 14, 20266-KReport of foreign issuer
- Sep 11, 20266-KReport of foreign issuer
- Sep 1, 20266-KReport of foreign issuer
- Aug 6, 20266-KReport of foreign issuer
- Aug 6, 20266-KReport of foreign issuer
- Jul 30, 20266-KReport of foreign issuer
- Jun 25, 20266-KReport of foreign issuer
- Jun 25, 20266-KReport of foreign issuer
- Jun 11, 20266-KReport of foreign issuer
Official filings of Cellectis S.A. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $73 M
- Operating income
- $-33 M
- Net income
- $-68 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $325 M
- Total liabilities
- $249 M
- Total equity
- $76 M
As of December-2025
Mutual funds holding Cellectis S.A.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Nomura Healthcare FundDelaware Management Company | 226,875 | $1 M | — | 0.09% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors | 223,114 | $1 M | — | <0.01% | −34% | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 2 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Markets and events: Cellectis S.A.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Fails to deliver
- : 6,582 shares at $1.10
- : 7,056 shares at $1.18
- : 9 shares at $1.41
- : 90 shares at $1.43
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Cellectis S.A. scorecard#
Passes 4 of the 12 checks that could be worked out: strongest in growth (2 of 4), weakest in profitability (2 of 5). Fiscal year 2025.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth2 of 4
- ✓Revenue grew in the newest year75.8%Revenue up 75.8% in fiscal 2025.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-0.67 vs -0.41Diluted EPS -0.67 in fiscal 2025 against -0.41 the year before (report's currency).
- ✓Net income higher than five years earlier-$68 M-$68 M in fiscal 2025 against -$81 M in 2020.
- ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
Profitability2 of 5
- ✗Profitable in the newest year-$68 MNet income -$68 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✓Operating margin above its peers' median-45.4%-45.4% against Biotechnology's median of -60.5% (243 companies).
- ✗Return on equity above 15%-65.3%-65.3% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-45.4%-45.4% in fiscal 2025 against -467.8% in 2022.
Financial health0 of 2
- –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times-0.7×Operating income -0.7 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year10.7%Diluted shares up 10.7% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Cellectis S.A.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -45.4% | -60.5% | |
| Net margin | -92.7% | -68.9% | |
| Return on equity | -65.3% | -61.0% | |
| Revenue growth | 75.8% | 15.8% | |
| Free cash flow margin | -57.2% | -61.5% |
2of 7on the Piotroski tests of financial strength
- Net loss of $68 million, the 12th loss-making year in a row.
- Free cash flow was negative: -$42 million.
- The share count rose 10.7% in the year.
- Operating income covers the interest bill only -0.7 times.
Cellectis S.A.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 73+75.8%100% | 42+5397%100% | 0.8−96.1%100% | 19−36.8%100% | 30r57−40.6%100% | 51r74+236%100% | 15+19.3%100% | 13−49.5%100% | 25−43.8%100% | 45—100% | |
| Cost of revenue | 0—0.0% | 0−100%0.0% | 0.7−58.4%97.6% | 1.8−3.9%9.2% | 1.8r31−5.5%6.1% | 2.0r36−82.9%3.8% | 11+316%75.0% | 2.7+4.5%21.5% | 2.6—10.4% | — | |
| Research and development | 94+3.3%128% | 91+3.3%218% | 88−10.1%11609% | 98−17.3%509% | 118r129+52.9%388% | 77r87−16.3%151% | 92+20.2%606% | 77−3.4%601% | 79+1.0%315% | 78—175% | |
| Selling, general and administrative | 20+3.7%27.1% | 19+13.5%46.0% | 17−3.9%2227% | 17−23.5%91.3% | 23r38+1.6%75.4% | 23r44−47.7%44.1% | 43−9.0%283% | 47+5.6%371% | 45+3.1%178% | 43—96.9% | |
| Total costs and expenses | — | 109+2.1%262% | 106−7.7%14105% | 115−18.8%602% | 142r198+39.5%468% | 102r168−30.5%200% | 147+15.8%965% | 127+0.1%994% | 126+2.1%502% | 124—276% | |
| Operating income | −33—−45.3% | −60—−143% | −97—−12888% | −90—−468% | −103r−131—−341% | −42r−85—−82.9% | −124—−813% | −105—−825% | −93—−368% | −67—−150% | |
| Interest and finance income | 16−63.7%22.1% | 44+107%107% | 21+1818%2845% | 1.1+55.8%5.8% | 0.7r0.7−48.3%2.4% | 1.4r1.9−80.1%2.7% | 7.0+2.9%46.0% | 6.8+244%53.3% | 2.0+21.1%7.8% | 1.6—3.6% | |
| Interest expense and finance costs | 51+136%70.0% | 22−46.8%52.1% | 41+128%5383% | 18+175%92.9% | 6.5r7.7−59.8%21.4% | 16r18+344%31.6% | 3.6−4.8%23.9% | 3.8−79.2%30.0% | 18+158%72.6% | 7.1—15.8% | |
| Income before tax | −68—−93.2% | −37—−88.6% | −116—−15426% | −99—−514% | −97r−125—−319% | −54r−97—−105% | −115—−758% | −88—−694% | −104—−412% | −67—−150% | |
| Income tax | −0.4—−0.6% | 0−100%0.0% | 0.4+326%49.1% | 0.1r−0.1—0.5% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | |
| Income from continuing operations | −68—−92.7% | −37—−88.6% | −117—−15475% | −99—−515% | −97—−319% | −54—−105% | −115—−758% | −88—−694% | −104—−412% | −67—−150% | |
| Income from discontinued operations | 0—0.0% | 0−100%0.0% | 8.4—1112% | −15—−80.0% | −28r−125—−93.4% | −44r−97—−86.0% | −115—−758% | −88r0—−694% | 0—0.0% | 0—0.0% | |
| Net income including minority interests | −68—−92.7% | −37—−88.6% | −108—−14363% | −114—−595% | −125—−412% | −97—−191% | −115—−758% | −88—−694% | −104—−412% | −67—−150% | |
| Minority interests' share of net income | 0—0.0% | 0—0.0% | −7.4—−978% | −7.9—−41.2% | −11—−36.0% | −16—−32.1% | −13—−86.4% | −9.6—−75.7% | −4.3—−17.1% | — | |
| Net income attributable to shareholders | −68—−92.7% | −37—−88.6% | −101—−13385% | −106—−554% | −114—−376% | −81—−159% | −102—−672% | −79—−618% | −99—−395% | −67—−150% | |
| Earnings per share, basic | -0.67—— | -0.41—— | -1.77—— | -2.33—— | -2.55—— | -1.91—— | -2.41—— | -1.93—— | -2.78—— | -1.91—— | |
| Earnings per share, diluted | -0.67—— | -0.41—— | -1.77—— | -2.33—— | -2.55—— | -1.91—— | -2.41—— | -1.93—— | -2.78—— | -1.91—— | |
| Shares, weighted average (basic) | 100+10.7%— | 91+58.9%— | 57+25.2%— | 46+1.6%— | 45+5.5%— | 43+0.1%— | 42+4.1%— | 41+14.2%— | 36+1.2%— | 35—— | |
| Shares, weighted average (diluted) | 100+10.7%— | 91+58.9%— | 57+25.2%— | 46+1.6%— | 45—— | — | — | — | — | — | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 62−57.0%18.9% | 143+4.8%37.3% | 137+46.7%40.9% | 93r90−49.8%35.7% | 186−23.0%48.6% | 241−29.2%51.4% | 341−24.6%72.8% | 452+76.1%90.1% | 256+0.7%77.0% | 255—76.8% | |
| Receivables | 14+114%4.4% | 6.7+1080%1.8% | 0.6−26.3%0.2% | 0.8−96.2%0.3% | 20+294%5.3% | 5.2+74.8%1.1% | 3.0−0.4%0.6% | 3.0+7.9%0.6% | 2.8−24.1%0.8% | 3.6—1.1% | |
| Inventory | — | — | — | 0—0.0% | 0−100%0.0% | 1.6r1.6−44.8%0.3% | 2.9+953%0.6% | 0.3+10.0%0.1% | 0.3+112%0.1% | 0.1—0.0% | |
| Other current assets | 5.4−2.6%1.7% | 5.5−28.4%1.4% | 7.7−14.9%2.3% | 9.1−6.1%3.5% | 9.7−67.4%2.5% | 30+89.8%6.3% | 16+1.9%3.3% | 15+11.8%3.1% | 14+54.6%4.1% | 8.9—2.7% | |
| Current assets | — | — | — | 122−45.9%46.7% | 225−28.5%59.0% | 315−19.5%67.2% | 392−19.7%83.8% | 488+50.9%97.4% | 323+3.4%97.1% | 312r312—94.3% | |
| Property, plant and equipment | 39−15.5%11.9% | 46−16.1%12.0% | 55−14.1%16.4% | 64−19.3%24.4% | 79+10.0%20.6% | 72+202%15.3% | 24+172%5.1% | 8.7r10+20.8%1.7% | 7.2−57.2%2.2% | 17—5.1% | |
| Right-of-use (leased) assets | 24−21.1%7.3% | 30−21.3%7.8% | 38−14.0%11.4% | 44−36.2%16.9% | 69−6.0%18.2% | 74+61.9%15.7% | 46—9.8% | — | — | — | |
| Other intangible assets | 0.5−52.1%0.2% | 1.1—0.3% | — | — | — | — | — | — | — | — | |
| Non-current assets | 88−8.3%27.2% | 96−4.7%25.2% | 101−13.7%30.3% | 117−25.1%44.9% | 157+1.6%41.0% | 154+103%32.8% | 76+475%16.2% | 13+36.6%2.6% | 9.7−49.0%2.9% | 19—5.7% | |
| Total assets | 325−15.3%100% | 384+14.7%100% | 334+28.0%100% | 261−31.6%100% | 382−18.6%100% | 469+0.4%100% | 467−6.7%100% | 501+50.5%100% | 333+0.4%100% | 331—100% | |
| Current liabilities | 146−12.3%44.9% | 166+7.2%43.4% | 155+222%46.4% | 48−2.5%18.4% | 49−5.1%12.9% | 52−16.9%11.1% | 63+33.6%13.4% | 47+3.1%9.4% | 45r44−19.1%13.7% | 56—16.9% | |
| Lease liabilities (non-current) | 28−19.0%8.5% | 34−20.3%8.9% | 43−13.0%12.8% | 49−31.0%18.9% | 72−5.6%18.7% | 76+62.8%16.1% | 47+4472%10.0% | 1.0—0.2% | — | — | |
| Non-current liabilities | 103+19.5%31.7% | 86−8.7%22.5% | 94+30.6%28.2% | 72−24.9%27.7% | 96−11.4%25.2% | 109+120%23.1% | 49+1235%10.6% | 3.7+7.4%0.7% | 3.4+484%1.0% | 0.6—0.2% | |
| Total liabilities | 249−1.5%76.6% | 253+1.2%65.8% | 250—74.7% | — | — | — | — | — | — | — | |
| Retained earnings | — | — | — | — | — | −506—−108% | −406—−86.9% | −327—−65.2% | −254r−252—−76.2% | −210r−208—−63.3% | |
| Shareholders' equity | 76−42.1%23.4% | 131+54.7%34.2% | 85−28.2%25.3% | 118−46.7%45.2% | 221−22.0%57.9% | 284r276−9.9%60.4% | 315−23.0%67.4% | 409+54.5%81.7% | 265r267−2.9%79.6% | 273—82.3% | |
| Minority interests | — | — | 0−100%0.0% | 8.0−47.5%3.1% | 15−39.4%4.0% | 25r33−37.9%5.3% | 40−1.5%8.6% | 41+114%8.2% | 19+919%5.7% | 1.9r1.9—0.6% | |
| Total equity | 76−42.1%23.4% | 131+54.7%34.2% | 85−32.8%25.3% | 126−46.7%48.2% | 236−23.4%61.9% | 309−13.1%65.8% | 355r355−21.1%76.0% | 450+58.6%89.9% | 284r286+4.0%85.3% | 273r275—82.4% | |
| Total liabilities and equity | 325−15.3%100% | 384+14.7%100% | 334+28.0%100% | 261−31.6%100% | 382−18.6%100% | 469+0.4%100% | 467−6.7%100% | 501+50.5%100% | 333+0.4%100% | 331—100% | |
| Shares outstanding | 100+0.2%— | 100+39.5%— | 72+57.1%— | 46+0.4%— | 45+6.3%— | 43+0.7%— | 42+0.1%— | 42+18.0%— | 36+1.8%— | 35—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 20+1.1%27.5% | 20+7.1%47.8% | 19+0.5%2453% | 18+30.2%96.2% | 14r17+80.7%46.6% | 7.8r9.8+13.9%15.3% | 6.9+189%45.3% | 2.4−29.5%18.7% | 3.4+52.5%13.4% | 2.2—4.9% | |
| Share-based compensation | 6.1+92.9%8.4% | 3.2−39.5%7.6% | 5.2−13.4%693% | 6.0−47.4%31.5% | 11r13+14.6%37.9% | 10r17−62.7%19.6% | 27−27.8%177% | 37−26.2%292% | 50−14.0%200% | 59—131% | |
| Cash from operating activities | −39−271%−54.0% | 23—55.4% | −25—−3278% | −87—−456% | −105—−345% | −80r−80—−157% | −69—−455% | −68—−535% | −52—−208% | −33—−73.0% | |
| Capital expenditure | −2.4—−3.2% | −2.6—−6.2% | −1.1—−142% | −2.4—−12.7% | −19r−20—−61.1% | −44r−46—−86.3% | −13—−85.0% | −4.7—−37.0% | −2.4—−9.5% | −14—−30.6% | |
| Intangible assets bought | −1.2—−1.6% | −1.3—−3.0% | 0—0.0% | −0.0—−0.1% | −0.0—−0.0% | −0.3r−0.6—−0.7% | −0.0—−0.3% | −0.2—−1.3% | −0.3—−1.1% | −0.3—−0.8% | |
| Cash from investing activities | −29—−40.4% | −103—−248% | −16—−2054% | −2.8−138%−14.4% | 7.3—24.0% | −54—−106% | −36−201%−236% | 36+1897%280% | 1.8—7.1% | −53—−119% | |
| Debt issued | 0−100%0.0% | 23−21.8%55.9% | 30+416%3930% | 5.8—30.0% | 0—0.0% | — | — | — | — | — | |
| Debt repaid | −5.4—−7.4% | −5.0—−12.0% | −5.1—−676% | −1.3—−7.0% | 0—0.0% | — | 0—0.0% | −0.1—−1.0% | −0.0—−0.2% | −0.1—−0.2% | |
| Shares issued | — | — | — | −0.6−101%−3.0% | 45—147% | — | 0−100%0.0% | 186+6261%1464% | 2.9+311%11.6% | 0.7—1.6% | |
| Cash from financing activities | −17−119%−23.0% | 89+7.5%215% | 83+7137%10975% | 1.1−97.6%6.0% | 48+74.0%157% | 27r27—53.5% | −3.9−102%−25.4% | 236+473%1858% | 41+8408%164% | 0.5—1.1% | |
| Exchange-rate effect on cash | 3.9—5.4% | −2.8−411%−6.6% | 0.9—117% | −3.4—−17.5% | −5.8−173%−19.0% | 7.9r7.9—15.5% | −2.1—−13.8% | −8.9−180%−69.6% | 11—44.0% | −2.2—−4.9% | |
| Change in cash | −86−1021%−117% | 9.3−78.2%22.4% | 43—5643% | −89—−465% | −50—−164% | −107r−107—−210% | −109−153%−717% | 204—1602% | −9.3—−36.8% | −85—−191% | |
| Report | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Dec 31, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Cellectis S.A. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Countries and regions
- 🇫🇷 France$73 M100%+76%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
How Cellectis S.A. compares in Biotechnology
- Revenue$73 M · higher than 65% of 647
- Net margin-92.7% · higher than 42% of 408
- Revenue growth75.8% · higher than 80% of 438
- 🇮🇱 Compugen Ltd.$73 M
- 🇬🇧 Bicycle Therapeutics PLC$249 M
- 🇺🇸 Assembly Biosciences, Inc.$434 M
- 🇩🇪 CureVac N.V.$74 M
- 🇺🇸 Recursion Pharmaceuticals, Inc.$2.6 B
- 🇺🇸 Zogenix$75 M
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Cellectis S.A.🇫🇷 | $216 M | — | -92.7% | +75.8% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Market cap:
- Jan 5, 2024 (last known)
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Cellectis S.A.? Verify and update this profile — free
Show Cellectis S.A.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.